Thyroid eye drug trial halted early – what we know
NCT ID NCT04737330
First seen Apr 24, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study tested a drug called secukinumab in adults with active, moderate-to-severe thyroid eye disease, a rare autoimmune condition that causes eye bulging and inflammation. The trial was stopped early, so only limited data were collected. The goal was to see if the drug could reduce eye bulging and inflammation, but no firm conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Frankfurt, 60318, Germany
-
Novartis Investigative Site
Freiburg im Breisgau, 79106, Germany
-
Novartis Investigative Site
Göttingen, 37075, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany
Conditions
Explore the condition pages connected to this study.